<qa>  What is the name of the treatment that patients may have received?To assess activity of abiraterone-re-challenge in patients with advanced prostate cancer and prior response to abiraterone. CRPC patients with prior response to abiraterone confirmed PSA Response and progression can be re-challenged with abiraterone. Patients may have received treatment with docetaxel, enzalutamide and radium-223. 